A5064391478- Colorectal Cancer Treatments and Studies
- Cancer Genomics and Diagnostics
- Lung Cancer Treatments and Mutations
- Chronic Lymphocytic Leukemia Research
- Gastric Cancer Management and Outcomes
- Gastrointestinal Tumor Research and Treatment
- Acute Myeloid Leukemia Research
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Lymphoma Diagnosis and Treatment
- Viral-associated cancers and disorders
- Angiogenesis and VEGF in Cancer
- Acute Lymphoblastic Leukemia research
- Cell death mechanisms and regulation
- Vascular Tumors and Angiosarcomas
- Cancer Immunotherapy and Biomarkers
- Sarcoma Diagnosis and Treatment
- Cancer Treatment and Pharmacology
- Neutropenia and Cancer Infections
- Head and Neck Cancer Studies
- Advanced Breast Cancer Therapies
- Protease and Inhibitor Mechanisms
- Hematopoietic Stem Cell Transplantation
- BRCA gene mutations in cancer
- Gallbladder and Bile Duct Disorders
- CNS Lymphoma Diagnosis and Treatment
Acıbadem Adana Hospital
2018-2025
Acıbadem University
2018-2019
Başkent University
2009-2012
Cukurova University
2002-2010
Adana Hospital
2009
Abstract Objective To evaluate the efficacy and safety of tislelizumab added to chemotherapy as first line (primary) treatment for advanced gastric or gastro-oesophageal junction adenocarcinoma compared with placebo plus chemotherapy. Design Randomised, double blind, controlled, phase 3 study. Setting 146 medical centres across Asia, Europe, North America, between 13 December 2018 28 February 2023. Participants 1657 patients aged ≥18 years human epidermal growth factor receptor 2 negative...
IntroductionThe phase 3 RATIONALE-303 trial (NCT03358875) investigated the efficacy and safety of tislelizumab versus docetaxel in pretreated patients with advanced NSCLC. Here, we report results describe exploratory biomarker analyses.MethodsA total 805 aged more than or equal to 18 years locally metastatic squamous nonsquamous NSCLC were randomized 2:1 intravenous 200 mg 75 mg/m2 every weeks. Co-primary end points overall survival (OS) intent-to-treat (ITT) programmed death-ligand 1...
Tislelizumab plus investigator-chosen chemotherapy (ICC) demonstrated a statistically significant improvement in overall survival (OS) versus placebo ICC RATIONALE-305 patients with locally advanced unresectable or metastatic human epidermal growth factor receptor 2 (HER2)-negative gastric cancer/gastroesophageal junction cancer (GC/GEJC) the intent-to-treat population and programmed death-ligand 1 (PD-L1) Tumor Area Positivity (TAP) score ≥ 5%. The United States Food Drug Administration...
Abstract Molecular oncology is the cornerstone for diagnosis, treatment, prognosis, and screening of individuals who present to an clinic. The integration molecular diagnostic techniques with therapeutic management patients has resulted in unique biomarker development improved clinical endpoints. Amongst all laboratory applied oncology, next generation sequencing (NGS) nucleic acids holds cardinal merit day. Multi-omic biomarkers are mainstay selecting variation-specific targeted therapy...
The PRAME (preferentially expressed antigen of melanoma) gene has been shown to be in high levels some solid tumors and hemopoietic neoplasias but not or only weakly normal tissues. It encodes an recognized by autologous cytolytic T lymphocytes. is a good candidate for tumor immunotherapy useful marker detection minimal residual disease (MRD). In this study, mRNA using real-time RT-PCR was studied 74 adult cases with acute leukemia-68 had de-novo leukemia, 3 chronic myeloid leukemia-blastic...
Based on the CheckMate 649 trial, nivolumab plus chemotherapy is recommended first-line treatment for HER2-negative unresectable advanced or metastatic gastric, gastroesophageal junction (GEJ), esophageal adenocarcinoma. This nationwide, multicenter, retrospective study evaluated real-world effectiveness of this regimen in Turkish patients and identified subgroups that may experience superior outcomes. Conducted across 16 oncology centers Turkey, retrospectively reviewed clinical charts...
Subset analyses from phase III evaluation of epidermal growth factor receptor inhibition (EGFRi) suggest improved outcomes in patients with EGFR-amplified gastroesophageal adenocarcinoma (GEA), but large-scale are lacking. This multi-institutional analysis sought to determine the role EGFRi largest cohort GEA date.A total 60 15 tertiary cancer centers six countries met inclusion criteria. These criteria required histologically confirmed metastatic or unresectable setting EGFR amplification...
Abstract Purpose Amplifications of receptor tyrosine kinases (RTKS) are therapeutic targets in multiple tumor types (e.g. HER2 breast cancer), and amplification the chromosome 4 segment harboring three RTKs KIT, PDGFRA, KDR (4q12amp) may be similarly targetable. The presence 4q12amp has been sporadically reported small specific series but a large-scale analysis is lacking. We assess pan-cancer landscape provide early clinical support for feasibility targeting this amplicon. Experimental...
We evaluated efficacy and toxicity profiles of fludarabine, Ara-C, idarubicin, G-CSF (Ida-FLAG) combination chemotherapy in 56 refractory and/or relapsed acute leukemia patients. Patients were treated with fludarabine phosphate 25 mg/m2/d (d1-5), Ara-C 2 g/m2/d idarubicin 12 (d1-3), was given subcutaneously from sixth day until absolute neutrophil count (ANC) >500/μL. One third the myeloblastic (AML) 45% lymphoblastic (ALL) cases primary disease. In AML patients, complete remission (CR)...
Background The management of the patients with carcinoma an unknown primary represents a difficult challenge in oncology. 18F-fluorodeoxyglucose positron emission tomography/computed tomography (FDG PET/CT) has provided new insights diagnosis, staging, and follow-up oncological patients. Aim This study aimed to investigate value FDG PET/CT clarifying site our histologically proven tumor metastasis (HPM) or high clinical suspicion malignancy, impact this technique on these Methods In total 94...
Abstract Results From RATIONALE 303: A Global Phase 3 Study of Tislelizumab (TIS) vs Docetaxel (TAX) as Second- or Third-Line Therapy for Patients With Locally Advanced Metastatic NSCLC Background: Anti-PD-1/L1 therapies have improved OS by 2-4 mo TAX in patients (pts) with advanced who progressed after platinum regimens. TIS is an anti-PD-1 antibody engineered to minimize FcγR binding on macrophages, a mechanism T-cell clearance and potential resistance. Methods: 303 (BGB-A317-303;...
Abstract The aim of this study is to detect the possible role hepatitis C Virus (HCV) in lymphomagenesis. HCV‐RNA and anti‐HCV antibodies were studied tissue serum samples taken from patients with non‐Hodgkin's Lymphoma (NHL). prevalence HCV, clinical presentation these cases, association histologic subtypes determined. RT‐PCR was used samples. tested microparticle enzyme immunoassay. Immunohistochemistry ABC method HCV core protein + cases. RNA could be detected 30 35 other tests performed...
Hand-foot syndrome (HFS), the most common toxicity of capecitabine, is characterized by tingling, numbness, pain, erythema, dryness, rash, swelling, increased pigmentation, and/or pruritus palmar plantar surfaces hands feet. HFS usually seen in both and feet, with varying severity. We have previously published a case report dihydropyrimidine dehydrogenase (DPD) deficiency that manifested variant HFS.We 65-year-old Turkish Cypriot male patient advanced gastric cancer who developed reddening...
330 Background: Tislelizumab (TIS), an anti-programmed cell death protein 1 monoclonal antibody, plus chemo, demonstrated significant overall survival (OS) benefit vs placebo (PBO) chemo (15.0 12.9 months [mo], hazard ratio [HR]=0.80, 95% confidence interval [CI]: 0.70, 0.92, P=0.0011) as first-line therapy in patients (pts) with advanced gastric or gastroesophageal junction adenocarcinoma (GC/GEJC) the randomized, double-blind, global, phase 3 RATIONALE-305 study (NCT03777657). Here we...
e16001 Background: Majority of patients with head and neck cancer present locally advanced disease. Most the are treated concurrent chemoradiotherapy. However, toxicities substantial can be associated severe local systemic toxicities. Alternate schedules cisplatin have been tried to overcome these No formal comparison, however, has reported between alternate reference regimen in literature. The primary aim is report a retrospective study comparing schedule standard three weekly bolus terms...